NewMarket Corporation: The Cash Cow, the Rocket-Propellant Option, and What the Market Now Prices

The business reason operating profit nevertheless increased is that NewMarket protected unit economics. Q2 benefited from pricing and surcharges intended to recover higher Middle East-related supply-chain costs, while operational efficiency and lower research/development/testing expense also helped. First-half operating margin rose to 22.1% from 21.7% even though shipment volume fell. This is evidence of pricing discipline and cost control, but it also means margins are currently doing more work than volume.

The terminal-value debate around additives is subtler than “EVs kill engine oil.” In 2025, roughly 85% of Petroleum Additives sales came from lubricant additives and about 15% from fuel additives. NewMarket says engine-oil products account for roughly 70% of lubricant-additive market volume, but that category includes passenger cars, motorcycles, heavy-duty vehicles, locomotives and marine applications. The remaining lubricant market includes driveline and industrial products, and Afton is developing fluids for electrified drivetrains, where conductivity, copper compatibility, thermal management, low friction and high rotational speeds create new formulation requirements. NewMarket does not disclose enough information to divide its own revenue into passenger-car engine oil, heavy-duty, marine, industrial and e-fluid buckets, which prevents a precise EV-exposure calculation.

That missing split is one of the most important blind spots in this report. The available evidence supports a plateau-to-gentle-decline thesis rather than a cliff. Installed internal-combustion fleets turn over much more slowly than new-car sales; heavy-duty, marine and industrial applications electrify more slowly; tighter engine and lubricant specifications raise formulation complexity; and driveline fluids survive the transition even when combustion engines disappear. Lubrizol's current passenger-car additive offering, for example, emphasizes low-speed-pre-ignition protection, timing-chain wear, cleanliness and fuel-economy requirements, illustrating how more demanding hardware creates additive value even when lubricant volumes are not growing.

My base long-term view is that Afton's physical shipment volume is around a plateau and can experience cyclical declines of several percent, as 2025 and first-half 2026 have already shown. I would not model a sudden collapse before the early 2030s, but I would also not capitalize this business as a perpetual mid-single-digit volume grower. Value per unit, mix, specification tightening and shareholder-friendly capital allocation can keep earnings healthier than volume. Eventually the shrinking passenger-car ICE fleet should become a structural headwind unless new e-fluid and non-passenger applications become large enough to replace it. That view is an inference from NewMarket's disclosed end markets and recent shipment performance rather than a company forecast.

Specialty Materials changes the terminal discussion because its scarcity is unusually tangible. NewMarket calls AMPAC a leading global ammonium-perchlorate producer and says it is aware of other U.S. capacity but believes those producers are not qualified for most U.S. Department of Defense and NASA programs. A 2017 GAO review went further historically, identifying American Pacific as the only U.S. company then certified to supply ammonium perchlorate for government launches. The barriers are therefore qualification, process consistency, particle-size specifications, safety infrastructure, environmental permitting and customer/program approval, not simply construction cost.

Calca has similar characteristics. NewMarket paid $218 million on 2025-10-01 for the Louisiana-based business and describes it as the nation's leading producer of Ultra Pure and high-purity hydrazine, with more than 70 years supplying high-purity hydrazine to DLA Energy. The seller, AeroEquity, described Calca more strongly as the sole domestic high-purity-hydrazine supplier to the U.S. government/DLA over that period. NewMarket's more conservative “leading producer” wording is the one I use for valuation because it is the buyer's SEC disclosure. DLA procurement records show an aerospace bulk HPH procurement period running from September 2025 through September 2030, confirming that government demand is organized on a multiyear horizon.

The demand side is accelerating. Northrop Grumman said in July 2025 that after investing roughly $1 billion in solid-rocket-motor capacity over six years, it intended to increase annual motor production from about 13,000 units to 25,000 by 2029. In August 2026, Northrop announced two agreements totaling $3 billion that include solid rocket motors and missile-defense components. L3Harris's Missile Solutions business has separately received a proposed $1 billion direct government investment framework, while L3Harris announced a billion-dollar-plus expansion of rocket-motor capacity in Virginia.

The customer map has also changed from the older “two U.S. motor makers” framing. Northrop's Orbital ATK heritage and L3Harris's Aerojet Rocketdyne remain the large incumbents, but Anduril emerged in 2025 as a third U.S. solid-rocket-motor supplier, targeting thousands of tactical motors annually. For AMPAC, a third qualified motor manufacturer is potentially positive: it increases aggregate domestic motor capacity and could diversify demand, provided Anduril uses propellant systems requiring AMPAC-qualified AP. The latter detail is not publicly established, so I do not include direct Anduril revenue in the valuation.

The capacity project is real rather than press speculation. NewMarket's 2025 10-K says AMPAC's project can cost up to $100 million, started in 2025, includes an additional production line, and is designed to increase ammonium-perchlorate capacity by more than 50%; management expected completion toward the end of 2026. The Q2 2026 filing narrowed total 2026 capital expenditure expectations to $100–130 million. Management also says hydrazine capacity is being expanded, but it has not disclosed the hydrazine project's dollar cost or percentage capacity increase.

This leads directly to the market-pricing question. At $947.02, NewMarket's equity value is $8.71 billion. Adding roughly $761 million of June-end net debt produces an enterprise value of about $9.47 billion. On a trailing basis Petroleum Additives is generating approximately $523 million of segment operating profit, while Specialty Materials is generating roughly $48 million. If one capitalizes the additives business at 14 times EBIT, it accounts for about $7.3 billion of enterprise value and leaves roughly $2.2 billion for Specialty Materials before separately capitalizing corporate overhead. At 15 times core EBIT, the specialty residual is still about $1.6 billion.

The defense business is no longer free at today's share price. Depending on the multiple assigned to Afton, the market is implicitly valuing Specialty Materials at approximately $1.1–2.7 billion. At a 14 times core EBIT assumption, that residual equals about 45 times Specialty Materials' current trailing EBIT, but about 24 times the roughly $90 million post-ramp EBIT I use in the base case. The market has moved from treating defense as an option to demanding that the option convert into earnings. This is also consistent with the stock's 2026 re-rating: one third-party decomposition shows the price rising about 43% from January 31 to August 17 while trailing revenue was essentially unchanged, with most of the move coming from P/E expansion from about 14 times to about 20 times.

That re-rating does not make the share price irrational. Current trailing P/E is about 20.4 times, versus estimates of roughly 15.5–17.2 times for NewMarket's ten-year historical average depending on data provider. The difference between providers is material enough that I would not claim a precise historical percentile, but both datasets agree that the current multiple sits meaningfully above its normal center and below the highest historical readings.

The company is financially capable of funding the transition. It produced $286.2 million of operating cash flow in the first half of 2026, spent $51.7 million on capital expenditures, paid $55.6 million of dividends and repurchased more than 200,000 shares for $126.4 million. Long-term debt declined to $854.8 million and management's net-debt-to-EBITDA measure fell to 1.0 times. With only 9.20 million shares outstanding, those repurchases matter materially to per-share arithmetic.

Using 200,000 shares as the minimum repurchased amount against approximately 9.40 million shares outstanding in February, the first-half pace equates to at least about 4.3% annualized share-count reduction if sustained. First-half net income grew 6.2%, while EPS grew 8.1%; roughly two percentage points of the difference therefore came from the shrinking denominator and related share-count effects rather than organic earnings growth. The cash spent on first-half repurchases, annualized against today's market capitalization, is a roughly 2.9% buyback yield; adding the current $12 annual dividend gives a roughly 4.2% gross shareholder-distribution yield at that spending pace.

The unresolved capital-allocation question is therefore marginal, not existential. NewMarket can fund the defense build and repurchase shares simultaneously. The harder question is where the next dollar should go at a $947 stock price. At roughly a 5% accounting earnings yield and a somewhat higher owner-earnings yield, repurchases are less compelling today than they were when the stock traded much lower. Additional Specialty Materials investment should take priority whenever capacity is backed by qualified demand and credible returns. Repurchases should remain the residual use of capital rather than compete with a scarce national-security capacity build. That is my capital-allocation view, not management guidance.

The qualitative portrait is company in transition. The old business is a mature, high-margin oligopoly with a long cash-generative runway but an eventual electrification question. The new business is small, volatile and still absorbing capital, yet occupies positions with far scarcer qualified supply and much better visible demand growth. The investment question has already moved beyond “does Specialty Materials have value?” The harder question at $947 is whether it can earn enough on the $915 million spent acquiring AMPAC and Calca, plus the capacity capital now being deployed, to justify the re-rating that has already occurred.

Company journey, financial vertical and capital-market narrative

NewMarket's corporate ancestry is unusually long, but today's economic identity is much younger. The lineage begins with Albemarle Paper Manufacturing Company in Richmond in the nineteenth century and intersects with the original Ethyl Corporation, the company formed by General Motors and Standard Oil of New Jersey in the 1920s to commercialize tetraethyl lead as an anti-knock gasoline additive. The modern company's predecessor acquired the original Ethyl business in 1962 and assumed the Ethyl name; decades of divestitures eventually concentrated the company around petroleum additives. University archival material confirms that General Motors and Standard Oil founded the original Ethyl enterprise, while NewMarket's own investor-relations archive links the present corporation to pre-2004 Ethyl filings.

That history matters because adaptation has always been part of the enterprise. Tetraethyl lead once sat at the center of the business, yet regulatory elimination of leaded automotive gasoline destroyed the economic basis of that product in major markets. The corporate lineage responded through diversification, spin-offs and eventually a focus on modern lubricant and fuel additives. The surviving asset was formulation, manufacturing, customer qualification and the ability to migrate into the next generation of performance chemistry, not one molecule.

The 2004 event that created the current ticker was a holding-company reorganization, not a conventional IPO. Ethyl Corporation announced that NewMarket Corporation would become the new parent on June 18, 2004; NewMarket shares began NYSE trading under NEU on June 21, replacing Ethyl's EY ticker. There was therefore no traditional IPO offering price or new-capital raise to analyze. NewMarket became parent of Ethyl, the business later branded as Afton, and associated subsidiaries.

The 2004 listing path was a corporate wrapper around an existing public business, not the birth of the economics investors own today. The more important strategic birth came from separating the modern Afton additive franchise from the old Ethyl identity and then investing in formulation, R&D, manufacturing and regional customer support as lubricant standards became more complex. By 2025 Afton employed roughly 450 people in research and development and operated a global manufacturing footprint serving North America, EMEAI, Asia-Pacific and Latin America.

The company's modern history can be understood in four stages.

The first was concentration around petroleum additives after the legacy conglomerate had shed unrelated activities. The strategic logic was attractive: additive packages make up a small fraction of the customer's lubricant or fuel bill but are essential to meeting engine, transmission and emissions specifications. The supplier therefore sells performance assurance rather than bulk chemistry alone. This became a four-player lubricant-additive structure in which Afton competes chiefly with Lubrizol, Infineum and Chevron Oronite. NewMarket's own filings still identify those names as its major lubricant-additive competitors.

The second stage was global expansion and cash compounding. The company reinvested in additive capacity, technical centers and customer qualifications while returning substantial capital to shareholders. The share count has steadily contracted over long periods, enhancing per-share compounding. By 2016 net income was $243.4 million and EPS $20.54; by 2020 net income had reached $270.6 million despite the pandemic year, although that figure included a $16.5 million gain on a non-operating real-estate sale.

The third stage exposed the commodity and inventory sensitivity underneath the moat. In 2021 petroleum-additive shipment volumes rose 11.7%, but raw-material and operating-cost inflation outran pricing, and group net income fell to $190.9 million from $270.6 million. Management's response was repeated price increases and margin recovery. In 2022 petroleum-additive sales reached about $2.8 billion and operating profit recovered to $378.2 million, with increased selling prices the principal contributor. In 2023 net income jumped to $388.9 million as pricing caught up and raw-material/inventory conditions normalized.

The key lesson from that episode is where Afton's apparent earnings stability comes from: the ability, with a lag, to pass a large part of input volatility through to customers while managing production and product mix, rather than stable raw-material prices. Revenue can therefore be inflated by raw-material pricing when input costs rise and compressed when they fall without proportional changes in economic profit. Yet 2025–26 shows the opposite risk: once price recovery is complete, genuine shipment weakness becomes visible.

The fourth stage began with AMPAC in January 2024. NewMarket paid approximately $697 million for the Cedar City, Utah ammonium-perchlorate producer. Purchase accounting allocated about $275 million to customer relationships, $60 million to formulas and technology, $30 million to trademarks, $29 million to water rights and $256 million to goodwill, among other assets and liabilities. AMPAC's results from the January 16 acquisition date through year-end 2024 included roughly $141 million of revenue.

The deal looked strange against NewMarket's prior identity: a mature lubricant-additive company suddenly bought a critical energetic-material supplier. In October 2025 the company made the direction clearer by paying $218 million for Calca, adding high-purity hydrazine to the portfolio. Preliminary purchase accounting assigned $171 million to identifiable intangibles and $48 million to goodwill, again showing that NewMarket paid chiefly for qualified customer relationships, process knowledge and scarcity rather than hard plant book value.

There is still an unresolved strategic contradiction. In its 2025 10-K NewMarket said its primary acquisition focus remained petroleum additives because management liked that business's risk-adjusted returns, even after spending roughly $915 million to establish the Specialty Materials platform. That wording suggests management still regards AMPAC and Calca as opportunistic adjacent investments rather than a declared transformation into a defense-materials holding company.

Financially, the long vertical record supports the screen that originally surfaced the company, but with important qualifications. NewMarket's 2016 net income of $243 million became $419 million in 2025, a modest long-term earnings CAGR at the corporate level. EPS grew faster because the share count fell. Revenue growth has been slower and more cyclical because additive prices move with raw materials, while margins and earnings have benefited from price/cost recovery and capital returns. The defense acquisitions now make comparisons with the pre-2024 company increasingly imperfect.

Cash conversion has been strong over a full cycle but highly lumpy year to year:

Across these five years, aggregate operating cash flow was about $1.94 billion versus $1.74 billion of aggregate net income, an OCF/net-income ratio of approximately 1.11 times. The weak conversion in 2021–22 largely reflected working-capital absorption during inflation and supply-chain disruption; 2023 then benefited from a $192 million inventory reduction, illustrating why any single year's FCF is a poor owner-earnings proxy.

Maintenance capex is not separately disclosed. A reasonable research estimate is roughly $60 million per year, anchored to pre-expansion annual capital spending around $48–79 million and the five-year average of roughly $64 million. The explicit AP expansion makes 2026 different: total capex is expected to be $100–130 million, so a material portion is clearly growth capital. On that estimated maintenance basis, 2025 owner earnings were approximately $509 million ($569 million OCF less $60 million maintenance capex), compared with $419 million of accounting net income.

At today's $8.71 billion equity capitalization, that 2025 owner-earnings estimate corresponds to about a 5.8% yield, versus a 4.9% trailing accounting earnings yield implied by the 20.4 times P/E. The difference is roughly 20%, below the framework's 30% threshold that would force owner earnings to replace accounting earnings as the principal valuation basis. I nevertheless use both because purchase-accounting amortization in Specialty Materials increasingly depresses accounting EBIT relative to economic cash generation.

Return on equity also needs decomposition rather than being accepted at face value. In 2025 net margin was about 15%, asset turnover was roughly 0.8 times and the average-equity multiplier was a little above 2 times, producing ROE in the mid-20s. The sources of that ROE are therefore high operating profitability plus a deliberately compact equity base, not exceptional asset turns. Buybacks reduce equity, while the AMPAC and Calca acquisitions have expanded the invested-capital base and goodwill/intangibles. ROIC is consequently a more demanding measure of the new strategy than historical ROE.

The acquisition record has not yet proved a high cash return. AMPAC cost roughly $697 million and Calca $218 million, a combined $915 million before subsequent expansion capex. Specialty Materials produced $47 million of 2025 operating profit, and first-half 2026 operating profit of $34.8 million annualizes arithmetically to about $69.5 million, though management's own warning against quarter annualization means that is not a reliable forecast. These figures imply only a mid-to-high-single-digit current accounting EBIT yield on acquisition cost. The thesis therefore requires the capacity ramp and Calca's full-year contribution to raise returns materially.

Calca's standalone revenue and earnings after acquisition are not disclosed, so a specific acquisition ROIC cannot be calculated from public information without inventing a profit allocation. That is a material disclosure gap. NewMarket has told investors what it paid and why the asset is scarce, but not yet enough to establish the actual return being earned on the $218 million purchase.

The balance sheet can absorb the experiment. NewMarket ended June 2026 with $93.6 million of cash, $854.8 million of long-term debt, about $589 million of unused revolver availability and management-defined net debt/EBITDA of 1.0 times. This is conservative for a company with approximately half a billion dollars of normalized owner earnings.

Governance is more complicated than the leverage. Thomas E. Gottwald has led NewMarket since the 2004 reorganization after serving as Ethyl's CEO from 2001. As of February 2026 he beneficially owned about 6.0% of the shares, while his father Bruce C. Gottwald held about 10.1%; the proxy says members of the Gottwald family may be deemed control persons. Directors and executive officers as a group held 8.6%, although that group figure overlaps Thomas's stake rather than adding to it.

Family involvement extends into management. The 2026 proxy identifies Daniel Gottwald as president of Ethyl, Clarke Gottwald as executive vice president of Specialty Materials and Edward Gottwald as senior vice president of procurement and data intelligence, all sons of Thomas Gottwald. The same filing reports related-party employment compensation and a 2025 residential-property sale to Daniel Gottwald at an asserted fair-market value of roughly $1.2 million. The structure creates real economic alignment through family ownership, but it also raises the governance standard investors should apply to succession, promotion and related-party decisions.

There is one class of common stock with one vote per share rather than a dual-class structure. I found no major accounting-fraud finding, forced auditor departure or similar financial-reporting event in the filings reviewed through Q2 2026; that statement is limited to the public record reviewed for this report rather than a guarantee that no dispute has ever existed.

The capital-market narrative has changed faster than the reported earnings base. NewMarket entered 2026 still priced largely like a mature specialty-chemical cash generator after 2025 petroleum-additive operating profit fell from a record $591.9 million to $520.1 million. By August the stock was near its 52-week high, at $947.02, even though trailing revenue had barely changed. A third-party decomposition places the January-to-August 2026 move almost entirely in multiple expansion rather than revenue or margin growth.

Historical valuation confirms a regime change. Macrotrends calculates a ten-year average P/E of about 15.5 times, while another historical dataset calculates about 17.2 times; the latter shows a 2018 peak near 26.9 times and a late-2024 trough near 11 times. The providers' methodology differs enough that a claimed exact percentile would be false precision. A defensible statement is that today's roughly 20 times trailing earnings is above NewMarket's long-run center and requires investors to value more than the old additive cash cow.

Business model, moat, industry structure and horizontal analysis

Petroleum Additives is the financial anchor. Afton develops additive packages that let base oils meet specifications for engine oils, automatic-transmission and driveline fluids, hydraulic oils, industrial gear lubricants, grease and other applications. Ethyl remains involved principally in fuel additives. The customer is buying a formulation that must perform inside expensive hardware under defined specifications, which makes additive cost small relative to the cost of failure.

The 2025 revenue mix makes the exposure clearer. Petroleum Additives generated about $2.53 billion of sales, of which roughly $2.16 billion came from lubricant additives and $378 million from fuel additives. Regionally, the business is diversified, with North America around 40% of petroleum-additive sales, EMEAI around 30%, Asia-Pacific around 20% and Latin America the balance. No single customer represented 10% or more of consolidated sales in 2025, although management still warns that a relatively small number of large lubricant and fuel customers matter economically.

The cost structure mixes chemical feedstocks, manufacturing assets, freight and logistics with unusually large technical and qualification expense. Raw materials make revenue look more commodity-sensitive than the profit pool really is because selling prices can be adjusted over time. Fixed manufacturing costs create negative operating leverage when NewMarket deliberately cuts plant production to manage inventory, as happened in Q4 2025. R&D is a standing obligation in the long run because engine and lubricant specifications keep moving; NewMarket increased technology investment even while pruning low-margin sales in 2025.

The strongest moat is customer qualification and switching cost. Lubricant formulators and OEM programs require packages to pass expensive sequences of engine, bench and field tests. A supplier that is already qualified can modify formulations alongside the customer's next specification cycle, while a new entrant must build labs, chemistry libraries, field history and trust. That helps explain why a global market large enough to support billions of dollars of annual sales still concentrates around four principal lubricant-additive suppliers.

The second moat is scale in formulation and manufacturing rather than pure scale in tonnage. Additive packages combine multiple chemistries and need local technical support across regions, fuels and hardware standards. Afton has hundreds of R&D personnel and a global plant/customer network. The market is therefore difficult to enter through one clever molecule: a challenger must reproduce a portfolio, technical support system and qualification history.

The third moat is industry structure. NewMarket identifies Lubrizol, Infineum and Chevron Oronite as its principal lubricant-additive competitors. Lubrizol is owned by Berkshire Hathaway; Infineum is a Shell/ExxonMobil joint venture; Oronite is part of Chevron. Two large rivals therefore sit inside integrated oil majors, whose economics may extend beyond the additive segment itself. Their segment profitability is not separately visible to public investors, making conventional margin discipline harder to observe.

That ownership cuts both ways. Captive ownership does not mean Infineum or Oronite is indifferent to profit, but an integrated parent can rationally care about lubricant formulations, refinery relationships and downstream system economics in addition to the standalone additive margin. Afton must earn an acceptable return directly for NewMarket shareholders. The result is an unusual oligopoly: barriers are high, but investors cannot assume competitors will always defend the same segment margin. This is an inference from disclosed ownership and competitive structure, not evidence of current predatory pricing.

Innospec is the nearest listed reference but not a true Afton clone. It operates Performance Chemicals, Fuel Specialties and Oilfield Services, so only Fuel Specialties directly overlaps a meaningful portion of NewMarket's fuel-additive franchise. In Q1 2026 Fuel Specialties generated $181.6 million of revenue and $37.8 million of operating income; Q2 produced $185.7 million and $36.3 million, margins of roughly 21% and 19.5%. Innospec had about $250 million of cash and no debt at June 2026. The comparison tells us that a roughly 20% operating margin in differentiated additive chemistry is achievable outside NewMarket, although Innospec's product mix is different.

Current prices and P/E figures are dated 2026-08-18. NewMarket and Innospec trade at strikingly similar headline earnings multiples even though NewMarket now contains the defense-materials option while Innospec has a net-cash balance sheet. Eastman is useful as a mature specialty-chemical valuation anchor, but its end-market and asset mix are substantially more cyclical, so I do not treat its multiple as a direct fair-value answer.

Sherwin-Williams and Ecolab show why the broader specialty-chemicals peer screen can mislead. On August 18 they traded at roughly 32 and 38 times trailing earnings respectively, premiums reflecting different business models, brands, customer-service density and growth characteristics. Applying those multiples to Afton because all three sit somewhere under “specialty chemicals” would overstate the value of a mature additive business with an explicit ICE terminal question.

The commodity-chemical contrast works in the opposite direction. NewMarket's products are small-value, high-consequence ingredients with qualification costs, so a commodity-spread multiple from Dow or LyondellBasell would understate the structural quality of Afton. The defensible pet-additive valuation range sits between bulk chemicals and premium service/brand specialty chemistry, with Innospec the most useful public checkpoint.

The core additive moat is real, but its terminal volume is the variable that determines how much investors should pay for it. In 2025 shipment volume fell 4.9%, mainly because of market softness and NewMarket's decision to cut low-margin business; in first-half 2026 volume fell another 5.3%. Those are too large to dismiss as an accounting artifact. Yet operating margins remained around 20–22%, showing that qualification and pricing discipline have so far protected economics as volume weakened.

The exposure bridge starts with the 85/15 lubricant/fuel mix. Within the broad lubricant-additive market, NewMarket says engine-oil applications represent about 70% of volume, with driveline and industrial lubricants making up the rest. Engine oil itself spans passenger vehicles and many non-passenger applications. This means passenger-car engine oil is materially less than 85% of Afton's business, but the filing does not give a precise percentage. Any model that applies passenger-EV adoption directly to 85% or 90% of NewMarket revenue is therefore structurally wrong.

Several forces offset electrification. An aging installed fleet and vehicle miles support maintenance demand. More demanding specifications raise the chemistry required to protect smaller, hotter and more efficient engines. Heavy-duty transport, marine, locomotives and industrial equipment are less exposed to near-term battery substitution. Driveline fluids persist in hybrids and EVs, and Afton explicitly invests in EV-fluid performance around electrical conductivity, copper protection, battery cooling and high-speed gearing.

Several forces push the other way. Longer oil-drain intervals reduce liters consumed per vehicle; improved fuel economy reduces fuel-additive throughput per mile; pure battery-electric vehicles remove crankcase engine oil entirely; and the recent shipment data show that cyclical softness can compound the structural transition. NewMarket's own business description names drain intervals, fleet size, miles driven, engine size and hardware/specification changes as the relevant variables.

My terminal assumption is therefore low nominal revenue growth with flat-to-mildly declining physical volume, not secular volume expansion. Through the early 2030s I expect product complexity, price/mix and non-passenger applications to keep Afton economically durable. Beyond that horizon, a declining passenger ICE stock should progressively reduce engine-oil demand unless e-fluid growth offsets more than today's disclosure lets investors prove. This assumption is why I use a 12–16 times EBIT range for the mature additives franchise rather than the 25–35 times multiples awarded to premium secular compounders.

Specialty Materials has a different moat. AMPAC manufactures ammonium perchlorate, the oxidizer used in many solid rocket propellant formulations. NewMarket says the material serves tactical and strategic missiles, rocket boosters, NASA and commercial space programs. The customer buys qualification rather than a commodity specification: purity, particle-size distribution, process consistency and approval on particular government and launch programs.

The historical industrial-base record illustrates how hard substitution can become. GAO reported in 2017 that the U.S. solid-rocket-motor base had consolidated from six suppliers in the mid-1990s to two major manufacturers and that both depended on a single U.S. firm for qualified AP; its footnote identified American Pacific as the only U.S. company then certified for government launches. A much older DoD Inspector General review of the AP supply chain describes government intervention after an explosion destroyed a large share of domestic capacity, including quantity guarantees and surcharges used to support replacement capacity. These historical arrangements prove strategic dependence, but they do not prove AMPAC's current contracts are take-or-pay or cost-plus.

Current contract economics remain opaque. NewMarket does not disclose whether AP sales are fixed-price, cost-plus, indexed or take-or-pay. It discloses customer-contract liabilities and prepayments at group level, but those cannot reliably be assigned to AMPAC. I therefore give no valuation credit for a take-or-pay structure. The moat rests on qualification scarcity and demand rather than assumed contractual protection.

Hydrazine has parallel barriers. Calca manufactures Ultra Pure and high-purity hydrazine used in spacecraft propulsion and government applications. NewMarket emphasizes stringent purity and reliability requirements and says alternative global producers are not all qualified. DLA continues to procure high-purity hydrazine as a dedicated aerospace-energy product, with current procurement extending through 2030.

The demand signal is unusually strong for both businesses. Northrop's plan to move solid-rocket-motor production from 13,000 to 25,000 units by 2029 represents a roughly 92% increase. L3Harris has announced large government-backed and internally funded rocket-motor expansions. Northrop's August 2026 agreements add a fresh multibillion-dollar missile-defense demand signal on top of those capacity plans. These announcements do not translate one-for-one into AP demand because motor sizes and formulations vary, but they show why NewMarket is expanding before the existing plants become the bottleneck.

For valuation, Northrop and L3Harris are customers/demand indicators rather than operating peers. Northrop traded around 18.7 times trailing earnings and L3Harris around 28.2 times on August 18. A supplier with higher concentration and less scale deserves no automatic premium to those primes; a sole/dominant qualified position with above-prime margins and faster incremental growth can nevertheless deserve a higher multiple than mature chemicals. That is why my Specialty Materials valuation range centers on 18–25 times post-ramp EBIT rather than borrowing either prime's P/E mechanically.

At full utilization, public data do not support a precise segment forecast. The AP line adds more than 50% AP capacity, but NewMarket does not disclose today's AP tonnage, revenue per pound, customer commitments or hydrazine capacity increment. I therefore model rather than “estimate” an undisclosed company forecast. My conservative post-ramp case is roughly $270 million of Specialty Materials revenue and $60 million EBIT; base is roughly $320–350 million and $85–95 million EBIT; optimistic is roughly $380–420 million and $105–120 million EBIT. The conditions are successful late-2026 commissioning, qualification of expanded output, continued motor production growth and enough demand to absorb the incremental capacity.

Those assumptions imply that incremental segment margins normalize below Q2 2026's 33.3% but above the trough Q1 outcome. That is deliberate. Purchase amortization remains in EBIT, while startup and qualification can depress early utilization; conversely, scarce capacity should produce meaningful fixed-cost leverage once loaded. Nothing in public disclosure supports a permanent 40% operating margin, even though individual quarters have exceeded that level.

The ecological niche is therefore unusually clear. Afton is a high-switching-cost oligopoly participant harvesting a mature global profit pool. AMPAC and Calca are qualification-constrained national-security suppliers at narrow bottlenecks. The first business's risk is slow erosion of underlying physical demand; the second's risk is that high apparent scarcity fails to convert into sustained returns after the capacity spending. Owning them together creates financial diversification and internal funding, but essentially no customer or product synergy.

Current fundamentals, valuation, risks and catalysts

The last four quarters trace the transition better than the year-over-year group figures.

Q3 2025 was burdened in Petroleum Additives by one-time charges linked to optimizing NewMarket's global manufacturing network, on top of weaker shipments and increased technology investment. Q4 then exposed the operating leverage: petroleum-additive sales fell to $585.1 million from $626.1 million, operating profit fell to $106.8 million from $135.7 million, and shipments declined about 6%. Management also reduced plant production to manage inventory, raising unit costs.

Specialty Materials moved the other way in Q4. Sales rose to $48.5 million from $27.1 million and operating profit to $7.3 million from $1.5 million, helped by AMPAC volume and the October 1 inclusion of Calca. NewMarket nevertheless repeated that quarterly segment results should vary materially because of product and contract timing.

Q1 2026 then delivered the report's most important warning. Petroleum Additives sales fell 5.5% and operating profit 5.0%, driven mainly by a 7% shipment decline associated with market softness and deliberate removal of low-margin business. The operating margin nevertheless held near 22.1%. Specialty Materials sales rose 8.2%, but operating profit fell 46.4%; management specifically identified AMPAC product-shipment mix as the principal cause.

Specialty Materials' Q1 collapse was genuine mix volatility, not an acquisition-accounting explanation invented to smooth the story. The acquisition creates amortization expense and the capacity expansion creates real spending, but NewMarket's direct explanation for the year-over-year Q1 profit drop was AMPAC shipment mix. That distinction matters because it implies the volatility can recur even after Calca integration is complete.

Q2 2026 was much stronger. Petroleum Additives sales rose 3.3%, operating profit 6.8%, and margin reached 22.1%. Yet shipment volumes were still down 3.8%; the revenue growth came from positive price/mix, including surcharges connected with Middle East-related supply-chain costs, plus currency. Specialty Materials sales increased almost 60% and operating profit more than doubled.

This pattern tells us what the next earnings report needs to answer. The first question is whether lubricant-additive shipment decline is moderating after -5.3% in the first half. The second is whether Afton can retain roughly 20%+ operating margins if surcharges normalize. The third is where Specialty Materials' margin lands after a 21% Q1 and 33% Q2. The fourth is whether management still expects AP and hydrazine capacity on line toward year-end.

Sell-side consensus is unusually thin. Nasdaq's earnings page currently displays no meaningful analyst-estimate dataset for NewMarket, and third-party earnings calendars largely infer the next report date from historical scheduling rather than company guidance. Investing.com currently estimates Q3 2026 reporting on October 26; MarketBeat labels the same date an estimate. Investors should treat 2026-10-26 as the expected, not company-confirmed, earnings date.

The market is trading a re-rating story more than a current revenue-growth story. A third-party decomposition of the move from January 31 to August 17 2026 attributes essentially the entire roughly 43% price increase to a higher P/E multiple: trailing revenue was about flat and net margin slightly lower, while the P/E expanded from about 13.9 to 20.1 times. That is consistent with investors capitalizing the defense-capacity narrative before the additional capacity contributes materially to revenue.

The bull/bear disagreement is consequently precise. Bulls see an additive franchise earning 20%+ segment margins despite a mid-single-digit shipment contraction, coupled with a defense-material bottleneck about to add more than 50% AP capacity into a market where Northrop plans nearly to double motor output and L3Harris is investing billions. Bears see a core business whose volumes are already declining, a specialty business whose first-half profit barely grew despite 31% sales growth, and a stock whose multiple has re-rated before the capacity proves its earnings return.

Cash-flow passthrough is good enough that accounting earnings are credible. The five-year OCF/net-income ratio is about 1.11 times, while 2025 owner earnings on my $60 million maintenance-capex estimate are about $509 million. Against today's market value that produces a roughly 5.8% owner-earnings yield. Reported 2025 FCF after all capex was $491 million, a 5.6% yield at the present market capitalization.

The maintenance/growth distinction becomes particularly important in 2026. Management expects $100–130 million of capital spending versus $78 million in 2025, with the AP capacity project alone costing up to $100 million over its multiyear construction period. Subtracting all 2026 capex as if it were maintenance would undervalue owner earnings; excluding all of it would overstate cash economics. My $60 million maintenance assumption is deliberately near the historical normal capital base, with the excess treated as growth.

The headline valuation is no longer cheap relative to NewMarket's own history. At $947.02 and trailing EPS of roughly $46.5, P/E is about 20.4 times. Macrotrends' ten-year average is around 15.5; another provider calculates 17.2. The current multiple is thus about 20–30% above the historical center depending on dataset, while still below the historical extreme.

The more useful valuation starts by separating the businesses. Trailing Petroleum Additives EBIT is approximately $522.5 million, calculated as 2025's $520.1 million plus H1 2026 $284.4 million less H1 2025 $281.9 million. Specialty Materials' equivalent trailing EBIT is roughly $48.0 million. Current enterprise value is about $9.47 billion using the August 18 market capitalization and June 30 net debt.

† Residual method before separately capitalizing corporate overhead; it therefore modestly overstates the value attributable solely to Specialty Materials.

This table is the answer to the central SOTP question. Afton would need a roughly 16 times EBIT valuation before the market leaves only about $1.1 billion for Specialty Materials. At a more conservative 13–15 times mature-core multiple, the implied specialty value is $1.6–2.7 billion. Since NewMarket paid about $915 million for AMPAC plus Calca before the current expansion program, the market now assumes significant value creation above purchase cost.

My base SOTP uses $525 million of normalized Petroleum Additives EBIT at 14.5 times and $90 million of post-ramp Specialty Materials EBIT at 22 times. That creates about $9.59 billion of enterprise value; subtracting current net debt yields roughly $8.83 billion of equity, or approximately $960 per current share. The $90 million specialty assumption is mine rather than reported guidance: it assumes roughly $320–350 million of revenue at a high-20s operating margin once expanded AP and hydrazine assets are productively loaded.

The conservative case uses $480 million of core EBIT at 12 times and $60 million of specialty EBIT at 18 times, yielding about $660 per share. The optimistic case uses $560 million of core EBIT at 16 times and $115 million of specialty EBIT at 25 times, yielding about $1,200 per share. These bookends intentionally make the core terminal multiple and the specialty ramp explicit rather than hiding them inside one group P/E.

† Includes roughly the current 1.3% dividend yield but excludes unpredictable repurchases.

This is valuation-scenario analysis within a research framework, not investment advice. Importantly, an independent owner-earnings cross-check produces similar values: roughly $430 million at 14 times gives equity value around $655 per share; $500 million at 17.5 times gives about $950; and $560 million at 20 times gives roughly $1,220. The agreement between SOTP and cash-flow methods is reassuring, but both depend on a core multiple that assumes Afton declines slowly rather than structurally breaking.

The base case's most fragile valuation assumption is the 14.5 times multiple on normalized core EBIT, because Afton still represents most enterprise value. Cutting that multiple to 70% of the assumption, 10.15 times, while leaving Specialty Materials unchanged reduces base SOTP from roughly $960 to about $712 per share. Cutting specialty EBIT to 70% instead reduces base value only to about $896. The stock therefore remains more sensitive to what investors ultimately believe about the mature cash cow than to one disappointing year of defense ramp.

The margin-of-safety test is unfavorable at today's price. Current $947 is roughly 43% above the conservative value around $660, so there is no discount to the conservative case. If EPS remains flat for three years and the current multiple does not change, the investor earns primarily the roughly 1.3% dividend yield; that is below the approximately 4.6% U.S. ten-year Treasury yield quoted on the research date. If NewMarket's P/E instead mean-reverts toward 15.5 times while EPS remains near $46.5, the terminal share price would be around $720 before dividends and the three-year total-return CAGR would be negative.

There is no margin of safety at this buy price.

Margin-of-safety sufficiency verdict: none.

The first permanent-loss risk is structural additive-volume erosion. I rate probability medium and impact high. The observable indicator is lubricant-additive shipments continuing to fall more than roughly 3% annually for several consecutive periods after the low-margin-business pruning is complete. The transmission path is direct: lower plant utilization raises unit costs, pricing loses its ability to offset volume, normalized EBIT falls below the $500 million area, and the market stops valuing Afton as a durable oligopoly. First-half 2026's -5.3% volume figure is already above that alert level; the open question is persistence.

The second risk is that Specialty Materials' scarcity proves less economically valuable than its strategic importance suggests. Probability is medium, impact high. AP demand can be strong while AMPAC still earns only ordinary returns if contract pricing is tightly controlled, qualification of new capacity takes longer than expected or customers qualify alternatives. The indicator is 2027 specialty revenue failing to move decisively above the roughly $250 million first-half-2026 annualized level, or operating margin staying below 20% after commissioning.

The third risk is schedule. Probability is medium, impact medium-to-high. Management has placed AP and hydrazine capacity toward the end of 2026, so a delay will be visible within months. Missing commercial production into Q1 2027 would push revenue to the right while depreciation, staffing and financing costs remain, creating a classic startup-margin squeeze precisely when the market is paying a higher multiple for the ramp.

The fourth risk is multiple compression. Probability is medium and impact high because 2026's stock return has come largely from re-rating. At the historical ten-year P/E around 15.5 times and today's trailing EPS, an unchanged business would trade close to the low-$700s. The catalyst need not be an earnings collapse; a softer defense-ramp narrative or evidence of persistent additive decline could be enough to reverse part of the multiple expansion.

The fifth risk is capital allocation and family governance. Probability of a destructive event is low-to-medium, impact medium. Insider/family ownership aligns management with per-share value, but multiple family members occupy senior operating posts, and management continues to describe petroleum additives as its primary M&A focus despite the defense platform now carrying the growth thesis. A large additives acquisition at a high multiple, or sustained buybacks above intrinsic value while qualified defense capacity remains underfunded, would be an observable negative signal.

Raw-material and geopolitical disruption is a sixth, lower-order risk. Middle East logistics increased costs in 2026, but NewMarket responded with surcharges and global production rebalancing. The danger becomes material if cost spikes move faster than price recovery for several quarters, recreating the 2021 margin compression rather than the successful 2026 Q2 pass-through.

The principal positive catalyst is simple: commissioning the AP and hydrazine capacity on schedule late in 2026, followed by evidence in early 2027 that customers are absorbing it. Northrop's planned motor-capacity ramp, its August 2026 missile-defense agreements and L3Harris's capital program give the demand story external validation that most small chemical expansions lack.

A second positive catalyst would be Petroleum Additives returning to flat or positive shipment growth while retaining a 20%+ operating margin. That combination would undermine the market's principal terminal-value concern and make the defense earnings genuinely incremental rather than a replacement for a shrinking cash cow.

Negative catalysts are equally identifiable: another specialty quarter resembling Q1 2026 without a clear mix explanation; a formal push-out of the capacity date; additive shipments remaining down mid-single digits into 2027; or an acquisition that diverts capital from the defense ramp. Because sell-side estimate coverage is thin, these operating datapoints matter more than “consensus beats” for price discovery.

† Third-party estimate, not yet a company-confirmed date.

The dashboard is designed to separate thesis variables from stock noise. Additive shipments and margins tell whether the old moat is still monetizing; specialty sales, margin and commissioning tell whether scarce assets are converting into profit; Northrop and L3Harris provide independent demand-chain confirmation; leverage and share count show what management is doing with cash; P/E shows how much optimism investors are already capitalizing.

Cross-synthesis and final research conclusion

Viewed vertically, NewMarket has proved one capability beyond doubt: it can operate a technically demanding, specification-driven chemical franchise for decades while adapting to changes in the products underneath it. The lineage survived the demise of leaded gasoline, rebuilt itself around modern lubricant and fuel additives, recovered margins after the 2021–22 raw-material shock, and has consistently generated enough cash to repurchase shares, pay dividends and fund new plants. The durable capability is formulation plus disciplined capital management, rather than attachment to one end market.

Part of past success came from favorable structure. Four large suppliers dominate lubricant additives, customer qualification is expensive, and the product is critical relative to its cost. That structure supported high margins and made price recovery possible after input shocks. Management deserves credit for operating inside the moat, pruning low-return volume and shrinking the share count, but investors should not confuse industry structure with managerial magic. If lubricant demand structurally declines, the oligopoly can share a shrinking profit pool.

The evidence says those historical advantages remain present today. Petroleum Additives retained a 22.1% first-half 2026 margin despite a 5.3% shipment contraction, which is exactly what a real moat should look like in an adverse volume environment: earnings resilience before revenue growth. The caveat is that the moat protects margin better than it creates end demand. Afton can take share, raise treat value and enter EV fluids, but it cannot make combustion-engine oil consumption grow forever.

Horizontally, Innospec supports the idea that additive chemistry can earn approximately 20% operating margins, while premium specialty names such as Sherwin-Williams and Ecolab show how much more the market pays for businesses with clearer secular growth. Afton belongs between those poles. It has more structural protection than commodity chemicals and a less certain terminal growth path than premium service/brand compounders.

The new defense-materials business has a different quality of advantage. AMPAC's AP is historically embedded in an industrial base where qualification has mattered enough for GAO to describe a single certified U.S. government-launch supplier. Calca's hydrazine has a similarly long government supply history. The external demand signals are unusually concrete: Northrop wants to move from 13,000 motors to 25,000 annually by 2029; L3Harris and the government are committing billions to rocket-motor capacity; Northrop announced further multibillion-dollar missile-defense agreements in August 2026.

Scarcity alone is not return on capital. NewMarket paid $697 million for AMPAC and $218 million for Calca, then committed up to $100 million to the AP expansion. Current specialty accounting EBIT remains small relative to that capital. The valuation needs $85–100 million-plus of sustainable segment EBIT after ramp for the acquisitions to look attractive on an accounting basis, and more if the market continues to value the business at a defense-growth multiple.

This is where the market has changed its mind. At the start of 2026, NewMarket could plausibly be described as an additives franchise with a defense option attached. By August the stock's P/E had expanded toward 20 times while trailing revenue was almost unchanged. At today's enterprise value, a 14 times EBIT value for Afton leaves more than $2 billion of value attributable to the remainder. Investors are already paying for a significant portion of Specialty Materials' prospective economics.

That does not mean the market is pricing the specialty business perfectly. At current earnings the implied residual looks expensive, because Q1 exposed severe mix volatility and the new capacity contributes no full utilization yet. On my base post-ramp EBIT of about $90 million, however, a roughly $2 billion residual corresponds to a low-20s EBIT multiple. That is defensible for a qualification-constrained national-security supplier growing into a severe missile-production bottleneck. The valuation is therefore a pre-paid execution thesis, priced neither as though defense were free nor as though it were a bubble.

Should the two businesses stay together? Through the 2026–27 capacity ramp, I think the answer is yes. Afton gives Specialty Materials cheap internal funding and the ability to build ahead of demand without stressing the balance sheet. Separating AMPAC and Calca today could impose financing, duplicated public-company cost and execution distraction exactly while major new lines are commissioning.

After the new capacity reaches a stable run rate, the strategic logic for permanent co-ownership becomes much weaker. There are essentially no customer, product or technology synergies between lubricant additives and rocket propellants. A standalone Specialty Materials company could eventually receive a cleaner defense-supply-chain valuation, while Afton could be priced explicitly on cash generation and the ICE terminal curve. Whether a separation would actually create net value depends on taxes, debt allocation, government/customer preferences and stranded corporate cost, none of which are publicly quantified. A spin-off conclusion today would therefore be speculative.

The largest likely market misjudgment is no longer that investors ignore Specialty Materials. The 2026 re-rating argues the opposite. The potential mispricing now sits in the shape of Afton's terminal curve. Investors who assume EV adoption creates a rapid cliff will undervalue the global installed fleet, heavy-duty, marine, industrial and driveline businesses; investors who extrapolate 20%+ margins indefinitely without modeling declining passenger-engine-oil volumes will overvalue it. The correct answer is a slow transition whose value depends heavily on the discount rate and terminal multiple.

Over the next year, the critical variables are the late-2026 capacity date, specialty mix, and whether additive shipment declines moderate. Over three years, the question is whether Specialty Materials reaches roughly $300–350 million-plus revenue and $85–100 million EBIT while Afton remains around $500 million EBIT. Over five years, the decisive variables are the slope of global combustion-lubricant demand and whether management uses the cash cow to build a durable second national-security platform rather than merely owning two acquired assets. These are research assumptions derived from the disclosed capacity program and current segment earnings, not corporate guidance.

Capital allocation should reflect that hierarchy. With net leverage around 1.0 times, management does not need to choose between basic shareholder returns and growth. But the marginal dollar should favor specialty capacity or acquisitions when they offer qualified, visible demand at double-digit prospective returns. Repurchasing stock around 20 times earnings is a weaker use of cash than repurchasing it at the 11–15 times multiples NewMarket has periodically traded at.

The current dividend remains easily supportable at $12 per share annually, but the dividend is not the investment thesis. Its roughly 1.3% yield is too small to protect investors from multiple compression. The buyback has more arithmetic power because the share count is only 9.2 million, yet buying back expensive shares transfers less value per dollar than retiring stock at lower multiples.

Bull reasons:

• Petroleum Additives preserved a 22.1% first-half operating margin despite a 5.3% shipment decline, evidence that qualification, price/mix and cost discipline still monetize the oligopoly moat.
• AMPAC's disclosed expansion adds more than 50% ammonium-perchlorate capacity and is scheduled toward year-end 2026, creating a near-dated growth catalyst rather than a distant concept.
• Northrop plans to raise annual solid-rocket-motor production from about 13,000 to 25,000 by 2029, while Northrop and L3Harris have announced billions of dollars of additional missile-production investment and agreements.
• Net debt/EBITDA is only 1.0 times, leaving NewMarket able to fund specialty growth, dividends and selective repurchases without balance-sheet stress.
• A 9.2-million-share base makes rational repurchases unusually powerful for EPS, and first-half 2026 EPS growth already exceeded net-income growth because the denominator contracted.

Bear reasons:

• First-half Petroleum Additives shipment volume fell 5.3%, with lubricant volumes the main drag; the core decline is a genuine volume issue rather than benign raw-material deflation.
• Specialty Materials' first-half sales rose about 31% while operating profit rose only about 3%, and Q1 margin collapsed from 43% to 21%, proving that product mix can overwhelm the growth narrative for individual periods.
• The stock trades around 20.4 times trailing earnings, materially above ten-year-average estimates of roughly 15.5–17.2 times after a 2026 rally driven principally by multiple expansion.
• The combined $915 million acquisition cost of AMPAC and Calca plus the capacity build has not yet produced a clearly high accounting return on invested capital; the thesis requires future utilization.
• NewMarket does not disclose the passenger-car/heavy-duty/industrial revenue split or current AP/hydrazine contract pricing, leaving two of the most important terminal-value variables unobservable.

The first pre-mortem is an additive de-rating. Assume 2027–28 lubricant shipments keep falling 4–5% annually after low-margin pruning is complete, Afton loses operating leverage and segment margin falls from roughly 22% to 17–18%. Petroleum Additives EBIT could fall toward $400 million. Investors then decide EV-driven decline has arrived earlier than expected and value the core at 10–11 times EBIT instead of 14–15 times. Even if Specialty Materials earns $90 million, SOTP can fall toward the $600s, roughly a one-third loss from today's price; a simultaneous specialty execution miss could push the drawdown toward 50%. The numerical path is a scenario stress test, not a forecast.

The second pre-mortem is a defense-ramp disappointment. Suppose the new line is delayed into late 2027, customer qualification takes longer, and Specialty Materials' revenue stays below $280 million with a margin around 18%. That would imply segment EBIT near $50 million rather than the $90 million base case. If investors then remove the defense premium and NewMarket's group P/E falls from about 20 times toward its 15–16 times historical center while Afton volumes are merely flat, the stock could move into the low-$700s. A broader core downturn at the same time creates the 50% loss script.

The final judgment rests on price rather than business quality. NewMarket has one proven, genuinely good cash-generating franchise and one genuinely scarce growth platform. The additive business deserves more credit than a commodity chemical company because switching cost and specification intensity have protected margin through difficult cycles. Specialty Materials deserves a defense-supply-chain premium because the qualification barriers and customer capacity announcements are real. At $947, however, investors are paying approximately fair base-case value for both. The defense business has already moved from an unpriced option to an execution obligation.

The strongest reason to own the company over three to five years would be evidence that the late-2026 capacity converts into $85–100 million-plus sustainable specialty EBIT while Afton stabilizes around $500 million. The strongest reason to wait is that today's price offers no protection if the core terminal multiple normalizes. A materially lower stock price can create a very different investment even with unchanged operations because NewMarket's cash generation and small share count make repurchases much more valuable at lower multiples.

【Company-profile scores】

• Fundamental quality: high
• Growth: medium
• Moat: strong
• Financial soundness: strong
• Management credibility: high
• Valuation attractiveness: medium
• Risk level: medium
• Suitable investor type: value / long-term growth / event-driven

【Investment rating】

• Rating: Hold
• One-line thesis: Afton's cash moat remains intact and defense capacity is valuable, but the 2026 re-rating already prices much of the post-ramp Specialty Materials case.
• Ideal buy price: see required line below.
• Acceptable hold price: 850–1,050 USD, surrounding the approximately $960 base SOTP and staying inside the framework's ±15% base-value discipline.
• Clearly overvalued price: 1,325–1,450 USD, beginning more than 10% above the roughly $1,200 optimistic valuation.
• Current-price classification: acceptable hold.
• Whether to wait for a better price: yes. A purchase becomes materially more attractive below about $525, or at a somewhat higher price only if new specialty capacity is operating, contracted utilization is visible and Petroleum Additives shipments have stabilized. The opportunity cost of waiting is missing the specialty-ramp upside if those conditions arrive without a price correction.
• Target holding horizon: 3–5 years.
• Expected annualized/12-month scenario return from $947: conservative approximately -29%; base approximately +3%; optimistic approximately +28%, including the current dividend yield but excluding unpredictable buybacks.
• Max-loss risk: roughly 40–50% in the combined pre-mortem where additive EBIT falls toward $400 million, the core receives a 10–11 times multiple and the defense-capacity ramp also disappoints.
• Reassessment triggers: Petroleum Additives volume remains below -3% for several consecutive reporting periods; segment margin falls below 18%; Specialty Materials margin is below 15% for two quarters; AP/hydrazine commercial ramp slips beyond Q1 2027; or net debt/EBITDA rises above 2.0 times without a clearly accretive acquisition.

【Ideal Buy Price】500–525 USD Basis: at least a 20% discount to the approximately $660 conservative SOTP, giving a real margin of safety against both additives multiple normalization and a slower Specialty Materials ramp.

【Valuation Range】

• current: 947.02 (close as of 2026-08-18)
• bear (conservative · ideal buy zone): [500, 525]
• base (fair · acceptable hold zone): [850, 1050]
• bull (optimistic · above the clearly-overvalued line): [1325, 1450]

Research uncertainties and source base

The first unresolved issue is end-use exposure inside Afton. NewMarket discloses lubricant versus fuel additives and describes engine-oil, driveline and industrial markets, but it does not disclose its own revenue split among passenger-car engine oil, heavy-duty diesel, marine, industrial, conventional driveline and e-fluids. That prevents an investment-grade numerical bridge from passenger EV penetration to Afton revenue. I therefore treat any precise “X% of NEU is exposed to EVs” claim as unsupported.

The second blind spot is contract economics in Specialty Materials. Public material establishes qualification scarcity and multiyear government demand, but not whether current AMPAC or Calca economics are take-or-pay, cost-plus, indexed or fixed-price. Historical government AP arrangements included quantity support and surcharges, yet carrying those terms into current contracts would be unjustified.

The third is Calca's standalone financial contribution. The $218 million purchase price and preliminary asset allocation are disclosed, but NewMarket does not break out Calca revenue, EBIT or cash flow after acquisition. The acquisition's realized ROIC therefore cannot yet be established from public information.

The fourth is the exact hydrazine expansion. Management says both ammonium-perchlorate and high-purity-hydrazine capacity are being expanded toward the end of 2026, but only the AP project has a disclosed “up to $100 million” cost and “more than 50%” capacity increase. Modeling a percentage hydrazine capacity uplift would be fabrication.

The fifth is capacity commitment. Demand signals from the motor manufacturers are unusually strong, but NewMarket does not disclose how much of its new AP line is pre-contracted. The valuation assumes industry demand becomes AMPAC utilization; the next stage of diligence should be judged from reported segment volume/revenue rather than from defense headlines alone.

The primary factual base for this report is NewMarket's 2025 Form 10-K, Q1 2026 and Q2 2026 filings/releases, and its 2026 proxy statement. Those sources establish the segment economics, sales bridges, acquisitions, capex program, competition, ownership and capital structure.

For industrial-base evidence I used U.S. GAO and Defense Department material on ammonium perchlorate and solid-rocket-motor supply, current DLA procurement information for hydrazine, and current disclosures by Northrop Grumman and L3Harris on rocket-motor capacity. These are more useful for Specialty Materials than generic commercial TAM studies because AP demand is program-, qualification- and capacity-driven.

For horizontal analysis, Innospec's SEC disclosures provide the nearest public additive-profit benchmark; Northrop and L3Harris are treated as demand-side comparables rather than direct specialty-material competitors. Current market prices and P/E values use the August 18, 2026 close where available.

Historical valuation providers disagree on NewMarket's exact ten-year average P/E, with estimates around 15.5 and 17.2 times. I retain the range rather than selecting whichever number better supports the valuation conclusion. Both sources agree today's roughly 20 times earnings is above the historical center.

Other tickers mentioned

• IOSP.US: Innospec is the nearest listed additive-company benchmark, especially through its Fuel Specialties segment.
• BRK-B.US: Berkshire Hathaway owns Lubrizol, one of Afton's three principal lubricant-additive competitors.
• XOM.US: ExxonMobil co-owns Infineum, a principal lubricant-additive competitor.
• SHEL.US: Shell co-owns Infineum with ExxonMobil.
• CVX.US: Chevron owns Oronite, another principal lubricant-additive competitor.
• EMN.US: Eastman provides a mature specialty-chemical valuation reference.
• SHW.US: Sherwin-Williams illustrates the premium multiple accorded to specialty-chemical businesses with different growth and customer economics.
• ECL.US: Ecolab is a premium specialty/service-chemicals contrast rather than a direct additive competitor.
• NOC.US: Northrop Grumman is a major solid-rocket-motor producer and direct demand indicator for ammonium perchlorate.
• LHX.US: L3Harris owns the Aerojet Rocketdyne-derived Missile Solutions business and is making major rocket-motor capacity investments.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.